恶性淋巴瘤是具有不同临床表现和潜在治愈可能的一组疾患。弥漫性大细胞型也是常见而最易治愈的类型之一。绝大部分学者认为,若能维持连续完全缓解(CR)达24月,则已治愈。近来作者发现超过上述时间仍有复发者,称之晚期复发。本文主要研究晚期复发者的临床、生物学特征及预测因素。503例连续初诊患者经治疗后383例(76%)取得CR,其中26例晚期复发。本文采用病理组织学分析,核酸流式细胞仪检查以及免疫表型(所用抗体为轻链泛—T及泛—B标记抗体)的方法对晚期复发病例进行研究,1例做bcl—2基因重组,24例进行了化 Malignant lymphomas are a group of disorders that have different clinical manifestations and potential cure potential. Diffuse large cell types are also one of the most common and most curable types. Most scholars believe that if they can maintain a continuous complete remission (CR) for 24 months, they have been cured. Recently, the authors found that there are still relapsers more than the above time, claiming a late relapse. This article focuses on the clinical, biological characteristics, and predictors of late recurrence. RESULTS CR was obtained in 383 consecutive patients (76%) after treatment. Among them, 26 cases had late recurrence. In this study, pathological histological analysis, nucleic acid flow cytometry and immunophenotype (the antibody used is light chain pan-T and pan-B labeled antibody) method for the study of advanced recurrence cases, 1 case of bcl-2 gene recombination , 24 cases have been